Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
http://seekingalpha.com/article/142868-hemispherix-and-antigenics-vaccine-adjuvants-indispensable-for-vaccines
Finally, there is general agreement that preventive vaccines (and therapeutic vaccines) are indispensable, especially when we are living an evolution when viral strains that used to infect species other than humans have begun to infect humans. These strains have severe symptoms and are, indeed, life-threatening. More important is that the strains mutate and we have to be prepared. Recent experiences came at the hands of H5N1 and swine flu viruses, which brought the fear that they might become pandemic as they acquire the ability for human-to-human transmission. The only way of prevention is effective vaccines.
Adjuvants are substance added to vaccines and other immunotherapies to enhance the body’s immune response to the antigen contained within the vaccine or treatment. Currently developed Adjuvants are playing a major role in the success of vaccines in boosting the immune system to prevent and cure infectious diseases and other diseases, including cancers. Here are some firms developing adjuvants. We begin with those that are currently put in the spotlight.
Promising Adjuvants:
1. Ampligen®
HEMISPHERX (HEB)
The innate immune system recognizes viral infection by identifying viral components, including double stranded (ds) RNA. Antiviral immune response is triggered in the mucosa of air passages.
Ampligen® (poly I:poly C12U) is a new class of specifically-configured ribonucleic acid (RNA) compounds developed by Hemispherx. It is a synthetic specifically configured double-stranded RNA containing regularly occurring regions of mismatching. Ampligen® and Oragens® experimental nucleic acids are being developed for the potential treatment of globally important viral diseases and disorders of the immune system including Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME), HIV, Hepatitis B, Hepatitis C, HPV, influenza and cancers including, kidney cancer and metastatic malignant melanoma.
Together with Defense R&D Canada, the National Institute of Infectious Diseases in Tokyo, the Princess Margaret Hospital in Hong Kong and the National Institutes of Health in the United States Hemispherx is conducting broad-based experimental studies to assess the efficacy of Ampligen®, Alferon N Injection® and Alferon LDO® as adjuvant single agent antiviral.
To date, >75,000 doses of Ampligen have been administered to humans, at an average dose of 400 mg, and it has been generally well tolerated
The intranasal inoculation with both the trivalent inactivated influenza vaccine + Ampligen(r) induced cross-protection mucosal immunity to H5N1 influenza virus in mice. Intranasal inoculation with both the annual influenza vaccine and Ampligen(r) may thus represent a strategy to generate protective mucosal immunity against newly emerging and highly pathogenic avian influenza viruses in humans.
Challenging trials clearly demonstrated that vaccine plus Ampligen adjuvant have been most effective versus all other treatment options. It is important to know that Ampligen may be used as an adjuvant for any other future influenza outbreak, not just Swine Flu.
Comments: A new peer reviewed publication titled "Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses" was published in Therapeutics and Clinical Risk Management 2009:5 125-132. The article summarizes ongoing research in which researchers conclude that Ampligen(r) is the "most promising adjuvant candidate for mucosal vaccines and produced cross-protection against variant influenza viruses not seen with the vaccines given alone.
Is this not the adjuvant task? Indeed it is and Ampligen has done it at best. We need adjuvants and Ampligen is among those whom we really need to have available to infectious disease and oncology specialists.
2. QS-21 Stimulon Adjuvant
ANTIGENICS (AGEN)
Antigenics’ QS-21 Stimulon adjuvant is used in various vaccines under development in trials for diseases, such as hepatitis, human immunodeficiency virus, influenza, cancer, Alzheimer’s disease, malaria, and tuberculosis;
QS-21 Stimulon is one of the world’s most widely studied adjuvants. Research has shown that when added to a vaccine, QS-21 has the potential ability to increase total vaccine-specific antibody response and T-cell response. In addition, QS-21 seems to increase potency of the vaccine with relatively small quantities of antigen and to exhibit synergy with other adjuvants.
Because of the ability of QS-21 to improve the body’s immune response to very low doses of antigen, vaccine antigen may be ‘spared,’ which could significantly decrease the amount of antigen required for a given dose and make vaccine production more economical.
Antigenics’ QS-21 is an integral part of experimental vaccines and treatments for conditions such as melanoma, malaria, HIV and other infectious diseases. Antigenics’ partners include GlaxoSmithKline (GSK), Wyeth-Lederle Vaccines, Aventis Pasteur, Progenics Pharmaceuticals and Elan Corporation (ELN).
Comments: We expects results from some vaccines developed by Antigenics’ partners to be positive and sales to begin with royalties paid to Antigenics for the use of its adjuvant. This good news is besides the good news about the firm’s therapeutic vaccine Oncophage for cancers, whose results were very promising. This cancer vaccine is approved in Russia and is waiting for approval to come from the E.U. to be followed by a U.S. approval.
Disclosure: No positions.
http://www.officialwire.com/main.php?action=posted_news&rid=4328
How Long Will FDA Keep Hemispherx Biopharma (Amex: HEB) On On Hold?
How long will FDA keep investors and chronic fatigue syndrome patients waiting for Ampligen decision?
Published on May 27, 2009
by M.E. Garza
(BioMedReports.com and OfficialWire)
LOS ANGELES, CA
Investors and CFS patients eagerly anticipating approval from the FDA on Hemispherx Biopharma's Ampligen may have to wait as much as 1-2 additional weeks for a decision according to the company's latest news release and Form 8K filing.
Trading on Tuesday sent shares up over 25% and volume was up over 4 times the daily average on the news as investors interpreted the development as a positive sign that approval for the drug may be coming.
Hemispherx Biopharma, Inc. (Amex:HEB), on Tuesday, announced that the U.S. Food and Drug administration (“FDA”) has advised the company that it may require up to 1-2 additional weeks to take action beyond the scheduled Prescription Drug User Fee Act action date of May 25, 2009 on the New Drug Application for Ampligen® (Poly I Poly C12U), a selective TLR3 modulator, for the management of Chronic Fatigue Syndrome. Reason for the possible delay was attributed by the Agency to certain staff scheduling changes which might (or might not) delay the report. Accordingly the Company’s development plan for Ampligen® continues as described in the recently filed 10Q and 10K, as the FDA did not request additional information from the Company at this time.
The delay has nothing to do with HEB or Ampligen and everything to do with the FDA, according to those familiar with the situation. In addition, the FDA did not request additional information.
Adrienne Dellwo, who serves as About.com's Guide to Fibromyalgia and Chronic Fatigue Syndrome had this to say to BioMedReports on the topic of Ampligen's approval:
"Of course, I hope that Ampligen will help a lot of people regain functionality and quality of life. With any new drug, however, it takes time to figure out just how effective it's going to be, and for how many people. On one hand, Ampligen's long, strange history casts some doubt on its effectiveness, but on the other hand some very prominent people in the CFS community have used it and believe it will change a lot of lives.
"The bottom line is that people with CFS need more treatment options, and studies show Ampligen may be a very good option, especially for certain CFS sub-groups. For example, it could work wonders for someone with a post-viral case, but not for those who developed it after exposure to toxins. I hope this is the treatment for which millions of people have waited."
Some are speculating that the delay may be, at least in part, due to the new appointment (confirmed by the Senate last week) of Dr. Margaret A. Hamburg, as the new commissioner of the Food and Drug Administration.
The Wall Street Journal has posted a story titled: "New FDA chief must divest several stock, fund holdings." In it, the Journal states that Margaret Hamburg and her husband, Peter Fitzhugh Brown, must divest themselves of several hedge-fund holdings as well as some of Mr. Brown's inherited drug-company stocks so Dr. Hamburg can take the post as the nation's top food and drug regulator.
Interestingly, a hedge-fund sponsor Renaissance Technologies, where Mr. Brown works owned 34,500 shares in HEB and added 23,000 more recently according to the latest Mutual Fund Facts report.
Hamburg is a former New York City health commissioner who also is a public health and bioterrorism expert. Hamburg told senators at her confirmation hearing that she wants to restore public confidence in the FDA by putting science first and by running an open and accountable operation. The FDA had been under criticism recently for its handling of several issues related to food and pharmaceutical products.
The company says it's development plan for Ampligen continues as described in their recently filed 10q and 10k.
Biotech investors interested in seeing the complete database of clinical trials and upcoming FDA decisions can access that information here:
http://biomedreports.com/component/content/article/548.html
The end of the trading day came on Tuesday. There was still no news of approval or denial from the FDA. Hemispherx Biopharma's (AMEX:HEB) Ampligen for Chronic Fatigue Syndrome spends yet another day in limbo.
By now, surely some of the company's investors are starting to feel like some of CEO, Dr. William Carter's patients.
Tired... Exhausted, even.
In the words of one blog, "Ampligen for Chronic Fatigue Syndrome: Another Deadline Come & Gone."
Adrienne Dellwo, about.com's resident expert on Fibromyalgia & CFS Guide wrote:
"First, a decision was due February 25. The FDA said it needed 3 more months to review data. The decision was then due on May 25, but on May 26 word came out that "staff scheduling changes" had delayed the final report. 1-2 more weeks, the FDA said. The 2 weeks were up yesterday, and still we have no word on whether Ampligen will become the first drug ever approved for chronic fatigue syndrome."
Some shareholders decided simply that they were "done waiting around" even as others urged them to "hold at least through the end of after hours trading" incase news of an approval came then. After all, we could now at least take comfort and confirm that the Phase III clinical trials for Ampligen's treatment of Chronic Fatigue Syndrome and Myalgic Encephalomyelitis were indeed over. News from the FDA had to be coming, any minute... No?
HEB shares had been trading at the $3 level for most of the day, but by the time 5 p.m. rolled around interest had... Well... Fatigued.
Now trading around the $2.80 mark, the faithful few who were still holding vigil got hit with a headline they weren't expecting at 5:29 p.m.: "Hemispherx (HEB) Sets Up for Another Offering."
"Wait. What?!"
Investors had seen this type of headline before and it wasn't the news they were waiting for.
"More dillution coming now?!"
As filed with the Securties and Exchange Commission on June 9th, Form S-3 from Hemispherx Biopharma, Inc. let the world be known that they were looking for a $150 million mixed securities shelf and that the offering would include common as well as preferred stock, warrants and debt securities.
Shares immediately started to tick down. Flatline basically. Investors in HEB had seen this before. Twice, in fact, during May.
"Crap! Not again. She's gonna drop like a rock, now."
But saavy investors started to quickly reconsider the value or importance of the filing.
We know that under a mixed securities shelf registration, a company may sell securities in one or more separate offerings with the size, price and terms to be determined at the time of sale. They may sell common and preferred stock as well as debt securities. But what did this all mean?
"Why now?"
As far as opinions go, HEB and it's backers have certaintly heard their fair (and unfair) share these past few weeks.
It has been just weeks, hasn't it?
What better time to take the pulse of the die-hards.. The do or die backers?
It's not like longs have anything better to do, right?
Here writes one such soul who goes by the name "my2ylws":
"The obvious is they need to raise alot of capital and fast and get Ampligen patented and to the marketplace as quickly as possible.
The SEC filing clearly states that they currently need partnerships:
"We have limited marketing and sales capability. We are dependent upon existing and, possibly future, marketing agreements and third party distribution agreements for our products in order to generate significant revenues and become profitable. As a result, any revenues received by us will be dependent in large part on the efforts of third parties, and there is no assurance that these efforts will be successful.
"Our commercialization strategy for Ampligen®-CFS may include licensing/co-marketing agreements utilizing the resources and capacities of a strategic partner(s). We are currently seeking worldwide marketing partner(s), with the goal of having a relationship in place before approval is obtained. In parallel to partnering discussions, appropriate pre-marketing activities will be undertaken. We intend to control manufacturing of Ampligen on a world-wide basis."
I think we will be hearing some "news" very soon.
Yeah. That's what they keep telling us.
Hey, speaking of news did you hear that there have actually already been some human trials for Ampligen as Vaccine Adjuvant?
Oh and did you know that the FDA and regulatory agencies worldwide have guidelines for accelerated approval of influenza vaccines and adjuvants?
I'm just sayin'... Oh look... After hours shares are starting to tick back up. They're headed back towards three dollars. That's a good thing, right?
Another long who goes by "hrtitech" opines the following:
"First, this is a preliminary step in advising as to an offering in the future and a legally necessary one that must be done in advance. It is also old news as the company previously alluded to increasing the float several days ago. I do not think the company will get the votes it needs to pass this offering unless the company has either been approved for CFS or Ampligen has been ordered as an adjuvant/booster.
"The company understands it will not be authorized without the support of sharelholders and they must know something positive is imminent. I think enough people agree with me to have traded a million shares after market and go from 2.56 to 2.96. The company is getting all their ducks in a row to be able to accomodate millions of needy patients. They simply do not have the infrastructure to accomodate them as we speak. I am sure countries and government agencies are insisting the company be able to meet the demand. There is something in law called a condition subsequent that may be met after the agreement has been executed. It allows for the parties to the contract to move forward with sufficient assurances there is a contract in hand.
"I think the answer is in the timing. Why did Carter wait until this afternoon to do his SEC dilution filing when the extensive documentation involved must have been prepared well in advance? My feeling is that by filing around the time when the market closes he is limiting his exposure to any adverse reactions. Following this reasoning leads me to believe that he feels the FDA will announce in the morning negating any adverse reaction from the dilution. Now whether or not the announcement is positive or negative is left to be seen. However, I believe that Carter feels it will be approved or else this timing strategy would not be necessary"
Oh look. After hours trading is over.
Loos like we'll have to wait until tomorrow...
Or the next day...
Or perhaps even next week to see what happens nex
http://biomedreports.com/articles/most-popular/1220-deciphering-hemispherx.html
Much to the delight of Hemispherx BioPharma individual and institutional investors, a reader and follower of StocksHaven Investments has identified several key points which have been raised recently, decyphering the fact from fiction.
The following article has been submitted by an investor named, Nick DeCesare
————-
After reviewing my own research, it is time to post some serious points, some of which have already been raised by other investors and some have not.
First of all, Mr. Feuerstein has questioned the safety record of Ampligen. The FACT is, when it began as a compassionate emergency treatment (granted by the FDA several years back), that very agency required HEB to submit monthly safety reports. As of approximately one year ago, the FDA contacted HEB via telephone call, to let them know these reports were no longer needed.
Mr. Feuerstein also questions the legitimacy of CFS as a real disease. Not only is it becoming more prominent and recognized across the country and world, but the CDC has been working closely with HEB to assure treatment of individuals with CFS as a result of their new CFS plan that is in the works (see link: http://www.cdc.gov/cfs/meetings/2009_04.htm). CFS has also been brought to the public’s attention in greater detail via peer reviewed papers touting its potential to cause serious suffering in an individual’s daily life.
Mr. Feuerstein also claims to have tried to contact Dr. Carter. This may be the biggest joke of all of his points. The FACT is, he never tried to get in touch with Dr. Carter via e-mail, phone, or any other means. He did however, get in touch with Dr. William Mitchell, who serves on HEB’s board. Dr. Mitchell is also a professor at Vanderbilt University and highly respected in the field of immunology. Apparently, Mr. Feuerstein had a hard time understanding the details of the conversation. This is no surprise because of his political science background. He is lacking any biological science background and therefore had trouble with the study results that were expressed to him. (see the StocksHaven Investments’ conference call with Dr. Carter).
Mr. Feuerstein also disputes the Phase 3 results from HEB, claiming the data is old and outdated and somewhat fabricated. The FACT is, the Phase 3 results were “consistently positive” as Dr. Carter states, with a final P value of 0.047, well within the 0.052 type range the FDA is looking for a drug to be under. The P value is basically the opportunity for the results to have happened by chance. The larger the P value, the more damaging the results of the study. Also, as Dr. Carter pointed out, Form 483 required by the FDA is filled out as a result of an exit interview for infractions on the drug results. There were no deficiencies in the results and HEB never had to address a Form 483 for the FDA.
Finally, Mr. Feuerstein discusses the failures of HEB, the inability to find a disease for Ampligen and how it has been kicking around for 30+ years. The FACT is, technology changes, technology changes quicker than we can keep up with it. As a result of technological changes, the ability to fine tune Ampligen to meet the needs of CFS has finally happened. What was not possible 5, 10, or even 15 years ago as a result of lack of technology, is available today. HEB has never been this close to bringing Ampligen to market for CFS, they have passed every major hurdle now as a result of these technological changes, it is a matter of time before approval.
A few final points. Many people point to the fact that HEB is not making money. They don’t have real profits. Let me say that the goal of a biotechnology company is to continue years of research which is funded any way possible, in order to one day bring a drug to market that will change the world and patient lives. If you can do this over many years, you have had success, HEB is almost there and will reap the benefits. This is not Pfizer or Merck, just a small biotechnology company with the greatest potential in its history right now. As Dr. Carter has pointed out many times, this is a detailed BIOLOGICAL SCIENCE that no POLITICAL SCIENCE person or anyone can fully grasp unless biological sciences is your background. He also firmly understands that it has taken HEB 15+ years to fine tune the drug for CFS. That is the nature of the beast.
Take into account my final two points. New molecular entities have an 80% approval rate, obviously great for HEB. Also, the HHS, Health and Human Services, which controls the FDA, and CDC, among other agencies), promoted the CFS advisory committee and all of their work. The HHS also supports the Agency Healthcare Research and Quality. Both the CDC and AHRQ both fully support Ampligen as a drug to help CFS.
If you ask my opinion, approval is on its way. Good luck all. Just needed to get some FACTS off my chest.
————-
Author Bio:
Nicholas DeCesare is an educator of 11 years in the state of Connecticut and holds a Master’s Degree in Education. He has been a freelance journalist for several local newspapers writing about topics ranging from investing to all aspects of technology. Nicholas has been investing in the stock market for the past 15 years with a particular focus on DRIP plans and biotechnology companies.
—-
Disclosure: Long-Term Position
—-
By reading StocksHaven Investments you agree to the disclaimer, and thereby will not hold Michael Vlaicu accountable for any transactions or decisions you make. It is up to you to do your own due diligence.
Random Posts
Bear Market Armageddon
FDA Watchlist - HEB
An Everlasting Milestone - Thank You
Daily Bargains - May/5/09 - QTWW & FAZ
WANTED DEAD or ALIVE!!!!!!!!!!!!!!!!!!!!!!
May 22, 2009. Palm Springs, Ca. A group of WaMu shareholders known as the Washington Equity Group (WaMuEquity.org) has announced it is offering a $1 Million reward for concrete evidence of any improprieties of JP Morgan Chase in the months preceding the takeover of Washington Mutual Bank.
A spokesman for the group is quoted as saying "A recovery from JPMorgan would be in the billions of dollars. The reward for direct evidence leading to such a recovery would come out of that recovery".
"What JP Morgan did to Washington Mutual is a travesty. They've done it before, and apparently a leopard can't change his spots".
The group urges anyone with direct knowledge and evidence of such criminal action on the part of JP Morgan Chase to come forward and 'do the right thing'.
Washington Equity Group has over 600 members, and can be contacted at their website: WaMuEquity.org.
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks…
WILMINGTON, Delaware (Reuters) - A bankruptcy court judge on Wednesday said she may rule by next month on efforts by Washington Mutual Inc to get back more than $4 billion in cash deposits to which it lost access when the bank was sold to JPMorgan Chase & Co (JPM.N) last year.
U.S. Bankruptcy Judge Mary Walrath said at a brief court hearing in Wilmington, Delaware, that she may decide on Washington Mutual's request for summary judgment on the matter before a June 24 scheduled court hearing.
http://www.reuters.com/article/businessNews/idUSTRE54J4AO200…
First Trade 0,123
2x 0,12 4x 0,123
bid 0,12 ask 0,119
50 mil milhões de dólares em causa
Mulher tentou maior fraude de sempre em Portugal
Ontem
As autoridades portuguesas estão a investigar uma tentativa de transferência de 50 mil milhões de dólares (36,6 mil milhões de euros) a partir do JP Morgan Chase, nos EUA, para Portugal, naquela que, se resultasse, seria a maior fraude de sempre no país.
A operação foi tentada por uma mulher não identificada, que apresentou num banco em Lisboa um contrato de transferência interbancária, ao qual a Lusa teve acesso, que previa uma movimentação de 36,4 milhões de euros na primeira tranche.
O documento levantou fortes suspeitas sobre a legalidade da operação que se pretendia concretizar, quer pelo modo de actuação da mulher, quer, sobretudo, pelo elevado montante envolvido.
Fonte oficial do Ministério Público disse à Lusa que "o Departamento Central de Investigação e Acção Penal (DCIAP) está a proceder à recolha de elementos sobre o assunto".
O Banco de Portugal também está a investigar o caso, segundo fonte oficial, que esclareceu que "o processo seguiu para o departamento de supervisão" da instituição liderada por Vítor Constâncio, confirmando ainda que os moldes do caso são semelhantes a outras tentativas de fraude detectadas pelas autoridades em Portugal.
A Unidade de Informação Financeira da Polícia Judiciária (PJ) também está ao corrente do processo. Contactada pela Lusa, fonte oficial da PJ disse que, no entanto, "não se considera oportuno o comentário sobre situações concretas", escusando-se a divulgar dados sobre situações do género detectadas nos últimos anos em Portugal.
Quanto ao valor envolvido, 50 mil milhões de dólares (36,6 mil milhões de euros), é de longe muito superior a qualquer outro caso semelhante alguma vez detectado em Portugal, confirmaram à Lusa o supervisor dos bancos.
Mesmo não existindo um limite definido para fazer transferências de dinheiro de Portugal para o estrangeiro e vice-versa, o montante é de tal forma elevado que daria para fazer cinco linhas de comboio de alta velocidade em Portugal ou dez aeroportos de Lisboa.
Se a operação fosse realizada, seria transferido para Portugal duas vezes o valor das 20 maiores empresas portuguesas em bolsa. "Uma quantia nunca vista, seja no mercado português ou em qualquer praça de referência do mundo", comentou uma fonte bancária à Lusa. De facto, não é todos os dias que se transferem 50 mil milhões de dólares de um país para o outro e, como referiu outra fonte de mercado, "até parece brincadeira. O valor é completamente anormal".
O contrato 'swift' [troca directa entre bancos] previa a transferência daquele motante entre o banco norte-americano, o JP Morgan Chase Manhattan Bank, e a instituição portuguesa, com uma taxa cambial pré-definida e fixa de 85 euros para cada 100 dólares (avaliando cada euro em 1,17 dólares - abaixo dos 1,36 dólares a que o euro tem sido negociado no mercado cambial).
A transacção realizar-se-ia em várias tranches, com a primeira fixada em 49,5 milhões de dólares (36,4 milhões de euros).
Em termos de comissões, o banco que aceitasse conduzir a operação de transferência do dinheiro receberia 2,5 por cento do montante global, isto é, 1,25 mil milhões de dólares (quase mil milhões de euros - o dobro do valor de mercado do Banif em bolsa, por exemplo).
Na página quatro do contrato lê-se que "as partes têm que seguir as coordenadas fornecidas pelas regras dos bancos sobre o Acto Anti-Terrorista e o Acto Patriótico I e II. O comprador [banco que aceita receber o dinheiro oriundo dos EUA] não será considerado responsável por nenhuma lavagem de dinheiro danosa".
Tags: Bolsa
FDIC, JPMorgan seek ouster of WaMu stakeholder suit
By Emily Chasan
NEW YORK, May 12 (Reuters) - U.S. bank regulators filed court papers this week seeking dismissal of a Texas lawsuit that claims JPMorgan Chase&Co (News/Aktienkurs) tried to gain an unfair advantage in its $1.9 billion purchase of Washington Mutual Inc' (News) s bank last year.
In documents filed on Monday in federal court in Galveston, Texas, the Federal Deposit Insurance Corp said the WaMu stakeholders who brought the lawsuit are trying to circumvent the FDIC claims process, and that the suit should be dismissed or moved to a court in Washington D.C.
WaMu collapsed last year, in the largest U.S. bank failure in history. The bank was seized by U.S. bank regulators on Sept. 25 and the FDIC immediately sold its deposits to JPMorgan. The surviving holding company filed for bankruptcy protection a day later.
However, the stakeholders' lawsuit filed in February claims that Washington Mutual's crown jewels were sold to JPMorgan at a fire-sale price that did not properly compensate WaMu's investors. They also claim that JPMorgan acted improperly ahead of the sale by leaking false and harmful information from WaMu's financial records, in an attempt to deflate its value and purchase WaMu's assets on the cheap, according to court papers.
The bankrupt holding company filed a request last week, asking for permission to investigate JPMorgan over the claims in the Texas lawsuit.
JPMorgan also filed court papers on Monday, saying it supported the FDIC's request, and that the stakeholders' claims in the Texas suit 'lack merit.'
The FDIC, which was not originally named in the investors' complaint, said it has sought to intervene in the case because it could be held liable for JPMorgan's costs in the litigation and that it needed to protect the FDIC receivership process used to take control of failed banks.
While the stakeholders have said their lawsuit is independent of the receivership process, the FDIC said in its court filing this week that the suit should be dismissed because it is 'especially important here to prevent the chilling effect that impermissible suits such as this one could have in deterring potential buyers of failed bank assets in the future.'
When the FDIC became the receiver for Washington Mutual Bank it said it agreed to protect JPMorgan Chase Bank from costs, losses, liabilities and expenses brought by WaMu's pre-receivership creditors.
The FDIC also said that JPMorgan Chase Bank sent a letter in March notifying the FDIC-Receiver 'of its intention to seek indemnification' in this case.
The case is American National Insurance Co v. JP Morgan Chase&Co, U.S. District Court, Southern District of Texas (Galveston), No. 09-00044.
(Reporting by Emily Chasan; Editing by Richard Chang) Keywords: FDIC/WAMU
(emily.chasan@thomsonreuters.com; +1 646 223 6114; Reuters Messaging: emily.chasan.reuters.com@reuters.net)
COPYRIGHT
Copyright Thomson Reuters 2009. All rights reserved.
The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
UPDATE 2-FDIC's Bair says U.S. needs systemic risk council
Wed May 6, 2009 7:18am BST
Email |Print | Reprints
[-] Text [+]
* Calls for regulator to oversee threats to financial system
* Should include Fed, Treasury, FDIC and SEC
* Also calls for regulator for big financial institutions
* FDIC chairman makes suggestions in prepared testimony (Adds background, Bair and Stern comments)
By John Poirier
WASHINGTON, May 6 (Reuters) - The United States needs a council of regulators to oversee threats to the financial system, in addition to a regulator to supervise the largest financial institutions, the head of the U.S. Federal Deposit Insurance Corp said.
In testimony prepared for delivery to the Senate Banking Committee on Wednesday, FDIC Chairman Sheila Bair said the Federal Reserve appears to be well-positioned to oversee systemically important firms.
However, she said a council that pulls in the U.S. Treasury, FDIC and Securities and Exchange Commission alongside the Fed should be charged with keeping an eye on system-wide risks.
"A distinction should be drawn between the direct supervision of systemically significant financial firms and the macro-prudential oversight of developing risks that may pose systemic risks to the U.S. financial system," Bair said in the testimony, obtained by Reuters. Continued...
Home
Business & Finance
Markets
UK Markets
US Markets
Europe
Asia
Analysis
Global Indices
Market Movers
Small Caps
Upgrades/Downgrades
Company Results and Outlooks
Paper Tips
Event Calendar
Dividend Calendar
Quotes
Deals
Global Industries
Currencies
Economy
Portfolio
Funds
IFA Research Centre
Personal Finance
Analyst Research
News
More News Today
Europe stocks rise after U.S. ADP jobs data
US STOCKS SNAPSHOT-Futures turn positive on ADP data
Video: Business Update: BofA shock absorbed
Video: Bernanke sees ray of light
Video: Investors await stress test results
More News...
UPDATE 2-FDIC's Bair says U.S. needs systemic risk council
Wed May 6, 2009 7:18am BST
Email |Print | Reprints
[-] Text [+]
To replace the current ad hoc approach, U.S. lawmakers are examining how to wind down financial institutions that have become "too big to fail" -- a designation forcing regulators to rescue them with taxpayer money because their demise could harm the U.S. financial system and the economy.
They are grappling with whether to prevent big firms from becoming too big or break up existing ones that may already be deemed too big for the U.S. financial system.
Another option being considered is whether they should be allowed to grow but impose systemic risk costs under an orderly resolution process.
Bair said in her testimony that the macro-prudential oversight requires many regulatory perspectives ranging from banks, securities firms, holding companies, among others.
"Only through these differing perspectives can there be a holistic view of developing risks to our system," she said.
Minneapolis Federal Reserve Bank President Gary Stern, in separate testimony, said U.S. regulators should tackle systemically important firms through tighter oversight and higher capital buffers and failure to do so could be costly.
"Maintaining the status quo with regard to TBTF (too big too fail) could well impose large costs on the U.S. economy. We cannot afford such costs," Stern said in his remarks.
Bear Stearns, Lehman Brothers, Merrill Lynch, American International Group Inc (AIG.N: Quote, Profile, Research), Washington Mutual, Wachovia, Fannie Mae and Freddie Mac are among the biggest casualties in the financial crisis stemming from subprime mortgage market.
Bair, whose agency manages receiverships, urged the committee to consider the FDIC's model for a resolution framework for handling troubled institutions of systemic importance. Continued...
UPDATE 2-FDIC's Bair says U.S. needs systemic risk council
Wed May 6, 2009 7:18am BST
Email |Print | Reprints
[-] Text [+]
"While no existing government agency, including the FDIC, has experience with resolving systemically important entities, probably no agency other than the FDIC currently has the kinds of skill sets necessary to perform resolution activities of this nature," Bair said.
She said that no single agency should decide to resolve a systemically important firm which should be given disincentives from growing too large by assessing fees depending on their size and complexity, she said.
She added that systemically important firms should be required to hold larger amounts of capital and liquidity buffers and face leverage restrictions.
Bair said cases of past bank failures had illustrated that taking over a depositary institution can be very complex because of the burdens placed on the parent company that could be forced into a costly bankruptcy proceeding.
As a result, the FDIC should also have the power to wind-down a failed banking depositary unit's holding company, Bair said.
"A realistic resolution regime would send a message that no institution is really too big to ultimately fail," she said.
Quinn Emanuel Sues Another Bank
By Andrew Longstreth
April 29, 2009
We've said it before and we'll say it again: It's a good time to be free of bank conflicts. Just take a look at Quinn Emanuel Urquhart Oliver & Hedges, which has been able to sue major financial institutions that most major firms can't. (And had profits per partner in 2008 of more than $3 million. Coincidence?)
Quinn's latest target is JPMorgan Chase & Co. On Monday the firm filed a suit against the bank on behalf of Washington Mutual Inc., which entered bankruptcy in September after the government closed its subsidiary, Washington Mutual Bank, and forced a fire sale of WaMu's assets to JPMorgan for $1.9 billion. In the complaint against JPMorgan, filed in Delaware bankruptcy court, Washington Mutual Inc. claims that JPMorgan "wrongfully withheld" more than $4 billion that it had deposited at Washington Mutual Bank. Quinn lawyers allege that Washington Mutual Inc.'s deposits should have be treated like any others acquired by JPMorgan when it took over Washington Mutual Bank's assets.
"The cornerstone of the agreement by which JPMC acquired the assets was that all bank depositors would have immediate and ready access to their cash on deposit at JPMC," the complaint says. "Despite the debtors' unquestionable right to their deposits, JPMC has refused to turn them over to the debtors. There can be no serious dispute that these funds, now on deposit with JPMC, are demand deposits and property of the debtors' estates."
A JPMorgan Chase spokesperson declined to comment to Reuters. No word yet on who's representing the bank.
http://www.law.com/jsp/tal/digestTAL.jsp?id=1202430293506&Qu…
http://revelationsmedia.com/wamu-truth-jp-morgan-and-fdic-co…
Of DOW JONES NEWSWIRES
NEW YORK -(Dow Jones)- Raymond James Financial Services, a unit of Raymond James Financial Inc. (RJF), recently recruited Ron Fetsch, a financial adviser, from WaMu Investments Inc., a division of JPMorgan Chase & Co. (JPM).
Fetsch, who joined Raymond James'Sunnyvale, Calif., office on Friday, had $ 2.8 million in trailing 12-month production and managed $300 million in client assets.
Before joining Raymond James, Fetsch worked at WaMu Investments for more than seven years, according to Financial Industry Regulatory Authority records.
A JPMorgan spokesman couldn't immediately confirm Fetsch's departure from the firm.
(STREET MOVES chronicles the migration of executives on Wall Street, with a particular emphasis on financial advisers with more than $1 million in annual production and who manage more than $100 million in client assets.)
-Brett Philbin, Dow Jones Newswires; 201-938-5393; brett.philbin@dowjones.com
(END) Dow Jones Newswires
04-29-091604ET
Copyright (c) 2009 Dow Jones & Company, Inc.
E-mail This Article to a Friend
SSHHOOOOOOOORTTT SSQQQQQQQQQUEEEEZZZZZZZEEEEEEEEEEEEE
Morning, today 1$$$$$$$$$$$$$$$$$$$$$$
Stock Preacher Issues Technical Trade Alerts on: AVII, SBUX, GNBT, GERN
VALLEY COTTAGE, N.Y., April 28 /PRNewswire/ -- StockPreacher.com announces the availability of Trade Alerts on stocks making news today.
Investors can view all of the daily updates for free by visiting: http://stockpreacher.com/
Today's Trade Alerts include: AVI BioPharma Inc. (NASDAQ:AVII) , Starbucks Corp. (NASDAQ:SBUX) , Generex Biotechnology Corp. (NASDAQ:GNBT) , Geron Corp. (NASDAQ:GERN)
StockPreacher.com's Trade Alerts are brief analyses on the active stocks each day that are affecting the markets. These include breaking news, insider activity, recent 52-week highs/lows, technical breakouts, and other market driving information. Stock Preacher is the authority on research in the small cap sector, and we strive each day to find the stocks that are poised to be the biggest movers before the rest of the market is aware of them.
We encourage investors to subscribe to our FREE newsletter filled with daily trading ideas by visiting: http://StockPreacher.com/stocktalk
StockPreacher.com is one of the industry's largest small cap research providers. Stock Preacher strives to provide a balanced view of many promising small cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the publicly available information available on them. For more information on Stock Preacher, please visit: http://StockPreacher.com CRD# 1603068
StockPreacher.com Disclosure
StockPreacher.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. StockPreacher.com is a wholly owned entity of Allan James Group, Inc., a financial public relations firm. Please read our report and visit our website, StockPreacher.com, for complete risks and disclosures.
Julio Serrano of Stock Preacher is a member of the National Association of Securities Dealers, CRD number 1603068.
DATASOURCE: Stock Preacher
CONTACT: Brady Middleditch of Stock Preacher, +1-604-871-4306,
Web Site: http://www.stockpreacher.com/
<< Back
Pre Market UUUPPP to .79!!!!!!!!!!!!!!!!
Float ???
Heathrow Natural Food & Beverage, Inc. Exfuze Sales Growing at Fifteen Percent per Month
Date : 04/13/2009 @ 8:30AM
Source : MarketWire
Stock : Heathrow Natural Food & amp; Beverage, Inc. (HRNF)
Quote : 0.0007 0.0 (0.00%) @ 8:42AM
Heathrow Natural Food & Beverage, Inc. Exfuze Sales Growing at Fifteen Percent per Month
LAKE MARY, FL -- (Marketwire) -- 04/13/09 -- Heathrow Natural Food & Beverage, Inc.
(PINKSHEETS: HRNF) is pleased to announce that its sales of the nutritional super drink Exfuze Seven + and Exfuze Seven + Pro (www.incredibledrink.com) are growing at fifteen percent per month. At this pace, HNFB projects sales for Exfuze to top $2 Million Dollars for 2009. Exfuze Seven + and Seven + Pro are a very powerful super botanical supplement beverage which delivers extreme anti oxidant values to the user. In fact, anti oxidant values, which are measured by the Oxygen Radical Absorbance Capacity scale (ORAC), rates Exfuze at 17,700 ORAC per ounce compared to 3,400 ORAC for three ounces of blueberries. The Exfuze products also deliver cell and immune system protection, along with anti stress reduction. Claims made are based on hundreds of clinical studies of the seven primary super food ingredients found in Exfuze Seven + and Exfuze Seven + Pro.
"As a user of Exfuze for almost two years, I can attest to the healthful benefits and significant increase in energy levels I have personally experienced. With close to 100 million baby boomers looking for the fountain of youth and a healthy and active lifestyle, the Exfuze products distributed by HNFB are perfectly positioned to capture its shares of the booming Wellenss Industry," said Michael Pagnano, CEO Heathrow Natural Food & Beverage, Inc. HNFB invites everyone to take the Free Exfuze Seven Day Challenge at www.incredibledrink.com and change your health for life.
Exfuze Seven + will also be featured on the upcoming airing of the WGL Million Dollar Shootout over a seven-week period on the Golf Channel beginning July 13, 2009. This will be seen by several million viewers with the reach and frequency to have a major impact on sales during the summer months of 2009 and beyond.
About Heathrow Natural Food & Beverage, Inc.: www.iexfuze.net/heathrow
Heathrow Natural Food & Beverage, Inc., is a national distributor of natural food products such as Exfuze, a very popular botanical nutritional beverage and the Heathrow Natural line of Super Food Products. HNFB is based in Florida and generates revenue through online and call center sales as well as over 138 distributors nationwide. HNFB also owns WGL Entertainment, the producer of the WGL Million Dollar Shootout reality television series.
Statements contained in this news release, other than those identifying historical facts, constitute "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934 and the Safe Harbor provisions as contained in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements relating to the Company's future expectations, including but not limited to revenues and earnings, technology efficacy, strategies and plans, are subject to safe harbors protection. Actual Company results and performance may be materially different from any future results, performance, strategies, plans, or achievements that may be expressed or implied by any such forward-looking statements. The Company disclaims any obligation to update or revise any forward-looking statements.
Contact:
Heathrow Natural Food & Beverage, Inc.
1-866-754-1115
CORRECTION FROM SOURCE: Patriot Energy Provides Complete Disclosure
Date : 04/07/2009 @ 12:58PM
Source : MarketWire
Stock : Patriot Energy Corporation (PGYC)
Quote : 0.0475 0.0 (0.00%) @ 7:14AM
CORRECTION FROM SOURCE: Patriot Energy Provides Complete Disclosure
MONTREAL, QUEBEC -- (Marketwire) -- 04/07/09 -- Patriot Energy Corporation (PINKSHEETS: PGYC) is pleased to provide its shareholders and stakeholders complete disclosure today.
All Cash Purchase Offer
The company has received an all cash purchase offer for all of the outstanding shares of the company at a price of $0.42 per share and a special royalty share, which will pay a $0.02 quarterly royalty.
Confidentiality of the Offering Party
According to the all cash purchase offer, the acquiring party is to remain confidential until all regulatory procedures have been met including but not limited to a vote in favor of the offer by the majority of shareholders through the mailing of the information circular to all shareholders and a shareholders meeting. The offering party does not want its identity disclosed until such time as the offer is accepted and shares are tendered in an attempt to avoid any market confusion on their own stock and its current trading levels.
Increase in Capital
The authorized capital of the company was increase to 1 billion shares from its original 200 million to allow the issuance of the special royalty shares as well as an issuance to the inventor and key management in lieu of a cash payment. The current issuance of shares are being done under rule 144 and are therefore restricted from resale and are included in the all cash purchase offer and therefore will not affect the price of the offer.
Position Report
Management did not and does not own any "free trading" shares. Management intends to acquire up to 32,000,000 shares and a position report of management's holding will be reported to shareholders in a timely manner.
Online Shareholders Vote
The company has received 152 shareholder votes online in favor of the all cash purchase offer and 2 shareholders have voted against. The number of shares is to be verified with each of the brokerage firms and cross referenced with the mailing and shareholders meeting as well as being audited by an independent firm to give it full force and effect.
About Patriot Energy Corporation
Patriot Energy Corp. is a management holding corporation, which owns a wholly owned subsidiary named TelTeck Solutions and owns a 99 year exclusive leased license agreement with Tectane Technologies Corporation for the Dual H2O Engine Oxygenator and New Tri-Brid Engine (Electric/Flex-Fuels/H2O) Technologies. Patriot Energy specializes in the development and marketing of energy efficient technologies with a focus on reducing America's dependence on Foreign Oil.
Total Shares Outstanding: 199,500,000
www.patriotenergycorporation.com
All statements in this news release that are other than statements of historical facts are forward-looking statements, which contain our current expectations about our future results. Forward-looking statements involve numerous risks and uncertainties. We have attempted to identify any forward-looking statements by using words such as "anticipates," "believes," "could," "expects," "intends," "may," "should" and other similar expressions. Although we believe that the expectations reflected in all of our forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct.
A number of factors may affect our future results and may cause those results to differ materially from those indicated in any forward-looking statements made by us or on our behalf. Such factors include our limited operating history; our need for significant capital to finance internal growth as well as strategic acquisitions; our ability to attract and retain key employees and strategic partners; our ability to achieve and maintain profitability; fluctuations in the trading price and volume of our stock; competition from other providers of similar products and services; and other unanticipated future events and conditions.
Contacts:
Momentum IR
Max Gagne
514-913-0351
877-253-7001
The names of the 500 Fortune Buyer
Pinnacle Digest: Patriot Energy Sparks Interest From One Of North America's Largest Online Investment Groups
Apr 06, 2009 (M2 PRESSWIRE via COMTEX) -- www.PinnacleDigest.com is a performance-driven online financial magazine and social network with a proven track record. After Friday's news from Patriot Energy Corporation (PINKSHEETS: PGYC) announcing that it has received a formal all cash purchase offer for all of the shares of the company at a price of $0.42 per share in addition to the special royalty unit, our team has launched their exclusive investor controlled forum. Our staff and members have requested that all Patriot Energy shareholders join our community and share their thoughts on the company, its development and future outlook. One of the most important aspects when we research for new investments is to understand the sentiment of the current shareholders; that is why we have released this announcement - we want to know your opinion.
Once a member of PinnacleDigest.com you will have access to all of our Patriot Energy research. It is our goal to find viable opportunities for each one of our members.
Join PinnacleDigest.com to Find out if Patriot Energy makes it as a Pinnacle Featured Company, Chat with other shareholders invested in Patriot Energy, Explain to our investor community what differentiates this company, Connect with investors and professionals in the equity markets, Meet the thousands of investors who have already become members of the Pinnacle community.
PinnacleDigest.com is an investment club comprised of over 15,000 members. We use all of our member's insight when selecting our next investment opportunity. Your membership is free - join today.
PinnacleDigest.com has no vested interest in the company mentioned herein. This source of information is from an unbiased perspective. If you wish to become a member of www.pinnacledigest.com you will be gaining access to articles similar to this one and many other useful services we know you will find valuable. Keeping you educated and up-to-date with the market is one of our main purposes. Our approach in achieving this goal and our ability to consistently deliver high quality investment material is what defines our business model.
This news release shall not constitute an offer to sell or the solicitation of any offer to buy securities in any jurisdiction.
All material herein was prepared by Pinnacledigest.com (Pinnacle Digest) based upon information believed to be reliable. The information contained herein is not guaranteed by Pinnacledigest.com to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Pinnacledigest.com is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. Pinnacledigest.com may receive compensation in cash or shares from independent third parties or from the companies mentioned.
Pinnacledigest.com will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.
You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and Pinnacledigest.com undertakes no obligation to update such statements.
CONTACT: Pinnacle Digest WWW: http://www.pinnacledigest.com
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
(C)1994-2009 M2 COMMUNICATIONS LTD
Who is Bottom??? Sorry
LOL, i hold my 6 Mil .shares !!!!!!!!!!!!!!!!!
I'm too by 17,have a nice weekend
OK at 15 I am waiting for your shares
I hold my 5 mil. Shares, yesterday i sold only 1 Mil.the next i sold after 0.01+
News by IVOT 10 Bagger today!!!!!!!!!
GREEN INNOVATIONS, INC. Eliminates the Convertible Feature Into Common Stock From Its Preferred Stock, Removing Dilutive Instr
MATAWAN, NJ -- (Marketwire) -- 03/19/09 -- iVoice Technology, Inc., d/b/a I GREEN INNOVATIONS, Inc. (OTCBB: IVOT) announced today that the Company has amended the rights of the holders of its Series A Secured Preferred Stock ("Preferred Stock") and has removed the right for holders to convert the Preferred Stock into the Company's Common Stock. The Company has $1.44 million of Preferred Stock issued and outstanding. Additionally, the Company also removed the right for holders of the Preferred Stock to vote their stock as Common Stock.
Jerry Mahoney, Chairman of I GREEN INNOVATIONS, said, "We have shown that we are committed to maximizing shareholder value for I Green Innovations by removing the last vestige of any potentially dilutive instrument from our balance sheet. We were able to accomplish this by showing our Preferred Stock holders the Company's potential for the future. Upon review, they agreed to the removal of the convertible feature from the Preferred Stock.
This eliminates a massive overhang on the Common Stock, as the Preferred Stock can no longer have an effect upon the number of outstanding Common Stock shares and cannot be dilutive to Common Stock shareholders."
Mahoney continued, "With our rapidly increasing distribution of our products, our stock buy-back program, and the potential in the market for 'Green' opportunities, we believe the Company is in a great position to deliver on its prospects. We are excited about the future, and look forward to making additional announcements on further developments in the coming weeks."
About B Green Innovations:
B Green Innovations, Inc. ("B Green"), a wholly owned subsidiary of I GREEN INNOVATIONS, a Matawan, and New Jersey-based corporation, is dedicated to becoming a "Green" technology company, focused on acquiring and identifying promising technologies that address environmental issues. The first technology will be used to create new products from recycled tire rubber.
Recently, we announced that we had filed a new patent application for a process it described as "paver blocks and patio blocks made from recycled tire crumb rubber." B Green Innovations, Inc. has also filed 3 additional patents applications on products using 100% recycled tires.
Certain information included in this press release, may contain forward-looking statements about our current and expected performance trends, growth plans, business goals and other matters. These statements may be contained in our filings with the Securities and Exchange Commission, in our press releases, in other written communications, and in oral statements made by or with the approval of one of our authorized officers. Information set forth in this press release contains various "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The Private Securities Litigation Reform Act of 1995 (the "Act") provides certain "safe harbor" provisions for forward-looking statements.
The reader is cautioned that such forward-looking statements are based on information available at the time and/or management's good faith belief with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the statements. Forward-looking statements speak only as of the date the statement was made. We assume no obligation to update forward-looking information to reflect actual results, changes in assumptions or changes in other factors affecting forward-looking information. Forward-looking statements are typically identified by the use of terms such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "predict," "project," "should," "will," and similar words, although some forward-looking statements are expressed differently. Although we believe that the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct.
For more information on I GREEN INNOVATIONS, please visit
http://www.bgreeninnovations.com/
http://www.igreeninnovations.com
Contact:
Dolores Serafin
732-696-9333
Today a Gapper by .0,004 ?
NEEEEWWWWSSSSSSSSSSSS!!!!!!!!!!!!!!!!
I GREEN INNOVATIONS, INC. Eliminates the Convertible Feature Into Common Stock From Its Preferred Stock, Removing Dilutive Instr
MATAWAN, NJ -- (Marketwire) -- 03/19/09 -- iVoice Technology, Inc., d/b/a I GREEN INNOVATIONS, Inc. (OTCBB: IVOT) announced today that the Company has amended the rights of the holders of its Series A Secured Preferred Stock ("Preferred Stock") and has removed the right for holders to convert the Preferred Stock into the Company's Common Stock. The Company has $1.44 million of Preferred Stock issued and outstanding. Additionally, the Company also removed the right for holders of the Preferred Stock to vote their stock as Common Stock.
Jerry Mahoney, Chairman of I GREEN INNOVATIONS, said, "We have shown that we are committed to maximizing shareholder value for I Green Innovations by removing the last vestige of any potentially dilutive instrument from our balance sheet. We were able to accomplish this by showing our Preferred Stock holders the Company's potential for the future. Upon review, they agreed to the removal of the convertible feature from the Preferred Stock.
This eliminates a massive overhang on the Common Stock, as the Preferred Stock can no longer have an effect upon the number of outstanding Common Stock shares and cannot be dilutive to Common Stock shareholders."
Mahoney continued, "With our rapidly increasing distribution of our products, our stock buy-back program, and the potential in the market for 'Green' opportunities, we believe the Company is in a great position to deliver on its prospects. We are excited about the future, and look forward to making additional announcements on further developments in the coming weeks."
About B Green Innovations:
B Green Innovations, Inc. ("B Green"), a wholly owned subsidiary of I GREEN INNOVATIONS, a Matawan, and New Jersey-based corporation, is dedicated to becoming a "Green" technology company, focused on acquiring and identifying promising technologies that address environmental issues. The first technology will be used to create new products from recycled tire rubber.
Recently, we announced that we had filed a new patent application for a process it described as "paver blocks and patio blocks made from recycled tire crumb rubber." B Green Innovations, Inc. has also filed 3 additional patents applications on products using 100% recycled tires.
Certain information included in this press release, may contain forward-looking statements about our current and expected performance trends, growth plans, business goals and other matters. These statements may be contained in our filings with the Securities and Exchange Commission, in our press releases, in other written communications, and in oral statements made by or with the approval of one of our authorized officers. Information set forth in this press release contains various "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The Private Securities Litigation Reform Act of 1995 (the "Act") provides certain "safe harbor" provisions for forward-looking statements.
The reader is cautioned that such forward-looking statements are based on information available at the time and/or management's good faith belief with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the statements. Forward-looking statements speak only as of the date the statement was made. We assume no obligation to update forward-looking information to reflect actual results, changes in assumptions or changes in other factors affecting forward-looking information. Forward-looking statements are typically identified by the use of terms such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "predict," "project," "should," "will," and similar words, although some forward-looking statements are expressed differently. Although we believe that the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct.
For more information on I GREEN INNOVATIONS, please visit
http://www.bgreeninnovations.com/
http://www.igreeninnovations.com
Contact:
Dolores Serafin
732-696-9333
MK now only 1.48 m.
NEEEWSSSSSSSSSSSS
Hard To Treat Diseases (HTDS) - Large scale integrating project HEALTH 2009
HTDS - IBISS GROUP COMPETED FOR THE EUROPEAN COLLABORATIVE PROJECT - LARGE SCALE INTEGRATING PROJECT HEALTH 2009
BELGRADE, March 17 /PRNewswire-FirstCall/ -- Hard to Treat Diseases (HTDS) http://www.htdsmedical.com/ is pleased to announce that the IBISS Group members from Slavica Biochem and part of a large International group of scientists, clinicians, management experts, small enterprises and industry from: Austria, Germany, Israel, Netherlands, Sweden, UK competed for the European Collaborative Project (large integrating project HEALTH 2009). Topics for single-stage submission and evaluation with a deadline of December 3, 2008 were successfully met by the company. Selection will be made sometime in 2009.
More details about the European Collaborative Project can be viewed by visiting these web site links.
http://ec.europa.eu/research/health/infectious-diseases/poverty-diseases/c all-for-proposals_en.html
http://ecentres.net/content/events/fp7-health-2009-single-stage_- _deadline_03_december_2008
The Indicative announced budget is EUR 476 million and focused on: BIOTECHNOLOGY, GENERIC TOOLS AND MEDICAL TECHNOLOGIES FOR HUMAN HEALTH
Slavica Biochem submission is on the Brain and brain-related diseases; as it relates to treatment of Multiple Sclerosis by means of stem cell therapy.
Get the Facts Right. The issuer works hard to continue to keep our shareholders informed, and news is updated frequently via Press Releases, Pink Sheet http://www.pinksheets.com/ filings, and updates to our websites. Other websites not sponsored, or recognized by the Company may provide misleading or disinformation to investors in order to manipulate trading patterns for a given stock. Always look for original content from trusted sources, rather than relying on 'excerpts' or discussion boards that may not give you the whole story. The Securities and Exchange Commission requires financial institutions or brokerage firms to provide their clients with documentation, describing the risks of investing in penny stocks.
CONTACT: For medical and scientific dialogue inquiry only, please contact Andrea Zecevic Hbsc. Msci; via e-mail at . Andrea Zecevic obtained her degrees at the University of Toronto Canada. Andrea Zecevic is the company's Chief Project Scientist, R&D and the Chief Liaison Director between the China and Serbia operating subsidiaries. For any corporate matters, readers should contact the company directly at
DATASOURCE: Hard to Treat Diseases
CONTACT: For medical and scientific dialogue inquiry only, please
contact Andrea Zecevic Hbsc. Msci; via e-mail at .
Andrea Zecevic obtained her degrees at the University of Toronto Canada.
Andrea Zecevic is the company's Chief Project Scientist, R&D and the Chief
Liaison Director between the China and Serbia operating subsidiaries. For any
corporate matters, readers should contact the company directly at
Next resistance .38
Support/Resistance
Type Value Conf.
resist. 1.80 4
resist. 0.69 5
resist. 0.61 2
resist. 0.52 6
resist. 0.38 3
resist. 0.13 28